Despite direct oral anticoagulants becoming a mainstay of anticoagulant therapy, the effective, timely, and safe reversal of their anticoagulant effect remains challenging. Emerging evidence attests that andexanet, a recombinant and inactive variant of native factor X (FXa), competitively inhibits and counteracts the anticoagulant effect of many inhibitors of native activated FXa.
Keywords: Anticoagulants; andexanet; antidote; apixaban; rivaroxaban.
Copyright © 2016 Elsevier Ltd. All rights reserved.